

# Dawid Walerych

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6434253/publications.pdf>

Version: 2024-02-01

20  
papers

1,337  
citations

759233

12  
h-index

752698

20  
g-index

21  
all docs

21  
docs citations

21  
times ranked

2506  
citing authors

#	ARTICLE	IF	CITATIONS
1	Parkin Levels Decrease in Fibroblasts With Progranulin (PGRN) Pathogenic Variants and in a Cellular Model of PGRN Deficiency. <i>Frontiers in Molecular Neuroscience</i> , 2021, 14, 676478.	2.9	12
2	A Driver Never Works Alone—Interplay Networks of Mutant p53, MYC, RAS, and Other Universal Oncogenic Drivers in Human Cancer. <i>Cancers</i> , 2020, 12, 1532.	3.7	12
3	Wild-type p53 oligomerizes more efficiently than p53 hot-spot mutants and overcomes mutant p53 gain-of-function via a “dominant-positive” mechanism. <i>Oncotarget</i> , 2018, 9, 32063-32080.	1.8	12
4	Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells. <i>Oncotarget</i> , 2018, 9, 20508-20523.	1.8	86
5	Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1. <i>Oncolimmunology</i> , 2017, 6, e1313371.	4.6	11
6	Targeting mutant p53 in cancer: a long road to precision therapy. <i>FEBS Journal</i> , 2017, 284, 837-850.	4.7	55
7	Mutant p53—Nrf2 axis regulates the proteasome machinery in cancer. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1217967.	0.7	12
8	Multi-omics reveals global effects of mutant p53 gain-of-function. <i>Cell Cycle</i> , 2016, 15, 3009-3010.	2.6	3
9	Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. <i>Nature Cell Biology</i> , 2016, 18, 897-909.	10.3	205
10	Mutant p53 inhibits miRNA biogenesis by interfering with the microprocessor complex. <i>Oncogene</i> , 2016, 35, 3760-3770.	5.9	43
11	Mutant p53: One, No One, and One Hundred Thousand. <i>Frontiers in Oncology</i> , 2015, 5, 289.	2.8	71
12	Cooperation of p53 Mutations with Other Oncogenic Alterations in Cancer. <i>Sub-Cellular Biochemistry</i> , 2014, 85, 41-70.	2.4	10
13	The rebel angel: mutant p53 as the driving oncogene in breast cancer. <i>Carcinogenesis</i> , 2012, 33, 2007-2017.	2.8	236
14	The diverse members of the mammalian HSP70 machine show distinct chaperone-like activities. <i>Biochemical Journal</i> , 2011, 435, 127-142.	3.7	163
15	ATP Binding to Hsp90 Is Sufficient for Effective Chaperoning of p53 Protein. <i>Journal of Biological Chemistry</i> , 2010, 285, 32020-32028.	3.4	34
16	The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin. <i>Molecular Cancer</i> , 2010, 9, 147.	19.2	26
17	Hsp70 molecular chaperones are required to support p53 tumor suppressor activity under stress conditions. <i>Oncogene</i> , 2009, 28, 4284-4294.	5.9	75
18	Psc3 cohesin of <i>Schizosaccharomyces pombe</i> : cell cycle analysis and identification of three distinct isoforms. <i>Biological Chemistry</i> , 2005, 386, 613-621.	2.5	2

#	ARTICLE	IF	CITATIONS
19	Hsp90 Regulates the Activity of Wild Type p53 under Physiological and Elevated Temperatures. Journal of Biological Chemistry, 2004, 279, 48846-48854.	3.4	135
20	Hsp90 Chaperones Wild-type p53 Tumor Suppressor Protein. Journal of Biological Chemistry, 2004, 279, 48836-48845.	3.4	134